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We have changed one of the carbohydrate-bearing asparagine residues of human antithrombin to glutamine by site-directed mutagenesis and 
expressed the variant antithrombin, N135Q, in baby hamster kidney cells. Two isoforms were secreted, both of which had higher affinity for heparin 
than human plasma a antithrombin. Both forms had normal inhibitory activity toward factor X, and showed normal heparin acceleration of 
proteinase inhibition. The mutation resulted in a higher production of the very high affinity form from about 30% to 60% of the total secreted 
antithrombin. This form should be the most useful for comparison of the effects of other mutations on heparin binding and proteinase inhibition. 
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1. I~RODUCTION 
Antithrombin is the principal inhibitor of the key 
blood coagulation serine proteinases, thrombin and fac- 
tor X, [l]. The rates at which it inhibits these proteinases 
can be greatly accelerated by binding to heparin at a 
distinct site on the inhibitor. Although the role of hepa- 
rin appears to be different for inhibition of each of these 
proteinases, involving predominantly conformational 
change in the case of factor X, inhibition [2], but a 
ternary complex, template mechanism in the case of 
thrombin in~bition [3], both types of inhibition require 
binding of a specific heparin pentasaccharide [4] to the 
heparin binding site of antithrombin. Binding of hepa- 
rin species containing this pentasaccharide to an- 
tithrombin results in a conformational change in the 
reactive center loop [5] where the inhibitor interacts 
with the target proteinase. 
bin, which, although having a heparin binding site dif- 
ferent from native antithrombin [6], serves as a useful 
starting point for identifying potentially important hep- 
arin-binding residues. 
In the absence of an X-ray crystallographic structure 
of either the antithrombin-heparin complex or an- 
tithrombin alone, site-directed mutagenesis n combina- 
tion with characterization of the structural and fimc- 
tional properties of the variant provides a useful means 
of evaluating the cont~bution of indi~dual residues to 
heparin binding and activation. This approach is also 
greatly aided by the availability of an X-ray structure 
of a proteolytically cleaved form of bovine antithrom- 
Since one of the main criteria for evaluating an amino 
acid substitution is the effect it has on heparin afiity, 
care must be taken with glycosylated recombinant an- 
tithrombins that equivalent carbohydrate isoforms are 
compared, since differences in the number and composi- 
tion of carbohydrate chains per se affect heparin affinity 
[7-l 11, We have shown that ~ycosylated recombinant 
human antithrombin (HAT) expressed in baby hamster 
kidney (BHK) cells was composed of three isoforms 
with different heparin affinities, that resulted from dif- 
ferences in carbohydrate content and composition [ 1 I]. 
Both to reduce the number of isoforms, thereby obtain- 
ing more antithrombin of one type from a given isola- 
tion, and to increase the affinity of the antithrombin, so 
that subsequent reductions caused by critical heparin 
binding site mutations do not effectively abolish heparin 
binding, we have prepared a variant antithrombin, 
Nl35Q, to mimic the high affinity B plasma form of 
HAT that lacks carbohydrate at residue 135. We de- 
scribe here the properties of the BHK-derived Nl35Q 
variant HAT and show that most of the original objec- 
tives were achieved by this mutation. 
*Corresponding author. Fax: (1) (615) 322 3141. 
2. MATERIALS AND METHODS 
Abbreviations: BHK, baby hamster kidney; HAT, human antithrom- 
bin; N135Q, variant of antithrombin in which Asp-135 has been 
changed to glutamine; forms I, II, and III represent differently glyco- 
sylated forms of wild-type recombinant human antithrombin with 
low, intermediate, and high atKnities for heparin; HAH, high afIinity 
heparin. 
2.1. Isolation of a and b forms of HAT 
a and /? plasma HATS were isolated from pooled outdated human 
plasma obtained from the Vanderbilt Blood Bank by affinity chroma- 
tography on heparinaepharose as previously described [ll]. Ion- 
exchange chromatography on DE 52 was used to remove any contam- 
inating heparin. Con~ntrations of both plasma and recombinant 
HATS were deal ~rophotome~~y using E&& = 6.5 [IZ]. 
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2.2. Production and isolation of re~o~~~nt HAT 
Site-directed mutagenesis of HAT cDNA was carried out in 
M13mp19 as described previously [S] using a single-stranded uracil- 
containing template and the anti-sense oligonucleotide 5’ CTT GGA 
GGA TTT CTG GGC TTT TCG ATA 3’ (the underlined triplet 
corresponds tothe asparagine-to-glutamine change). The mutated 
antithrombin cDNA was ligated into pMAStop, as described [5], to 
generate plasmid pMAAT3-N135Q. BHK cells were transfected with 
plasmids pMAAT3-N135Q, pRMH140, and pSV2dhfr and stable 
transfectants selected by resistance to neomycin and methotrexate, as 
described previously [13]. Antithrombin was isolated from serum-free 
growth medium of confluent cells as described [I I]. 
2.3. ~haructer~~ation of c~rbohydrute species on anfithro~in 
The types of carbohydrate present on the two isoforms of N135Q 
recombinant HAT were identified by use of a glycan differentiation 
kit (Boehringer-Mannheim) following the manufacturer’s directions, 
as described [l 11. 
2.4. Antithrombin assay 
The level of antithrombin secretion from BHK cells at various 
stages of the transfection and production procedures was monitored 
by radial immunodiffusion, using prepared plates containing sheep 
anti-HAT antibody (The Binding Site Ltd., Birmingham, UK). 
2.5. Fluorescence meusurements 
Fluorescence measurements were made on a SPEX sp~trofluo~me- 
ter, exciting at 295 nm and observing t~tophan emission at 335 nm. 
Heparin binding experiments were carried out as previously described 
[l I], and the resulting data fitted by non-linear least squares analysis 
using the program, MINSQ II (Micromath Scientific Software, Salt 
Lake City, UT). Because of the high affinity of the two recombinant 
antithrombin isoforms for heparin, Kd values were determined at 
0.3 I to lower the affinity and allow more accurate dissociation con- 
stants to be obtained. The buffer used was 20 mM sodium phosphate 
at pH 7.4 containing 0.1 mM EDTA, 0.1% polyethylene glycol 8000 
and 0.25 M NaCI. 
2.6. Factor X, nssay 
Rates of inhibition of factor X, by antithrombin species were meas- 
ured under pseudo-first order conditions. Second-order rate constants 
for the hepa~n-catalyzed jnhibition of factor X, were dete~ined in 
the presence of catalytic con~ntrations of heparin as previously de- 
scribed [14]. Concentrations of factor X, and antithrombin of 20 nM 
and 1 PM were used for all measurements. 
2.7. Materia1.s 
Spectrozyme X, was from American Diagnostica, Greenwich, CT, 
Dulbecco’s modified Eagle’s medium, fetal calf serum and neomycin 
were from Gibco; and methotrexate was from Sigma Chemical Co., 
St. Louis, MO. Thrombin was prepared from outdated human plasma 
by the method of Miletich et al. [IS] as described previously [I4]. 
Human factor X,, a gift from Dr. Paul Bock, Vanderbilt University, 
was prepared by affinity chromatography on soybean trypsin inhibi- 
tor-Sepharose [I$ M, 9,ooO high affinity heparin (HAH) was a gift 
from Dr. Steven Olson, Henry Ford Hospital, Detroit, and contained 
one high amnity binding site for antithrombin. Synthetic heparin 
pentasaccharide [4] was a gift from Dr. Jean Choay, Centre Choay. 
Plasmid pAT3c [17] was a gift from Dr. Susan Bock, Temple Univer- 
sity. Plasmids pMAStop, pRMH140, and pSV2dhfr 1131 were gifts 
from Dr. Gerd ZettlmeiDl, Behringwerke, Marburg. 
3. RESULTS 
3.1. Isolation of” recombinant HAT isoforms 
Two isoforms of recombinant N135Q HAT were iso- 
lated from the growth medium of stably transfected 
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Fig. 1. Elution profile of the two isoforms of recombinant human 
Nl35Q variant antithrombin from heparin-Sepharose. About 0.5 mg 
of each purified isoform was recombined and applied to the column 
equilibrated in 0.15 I buffer. The antithrombin species were eluted by 
a linear salt gradient in the same buffer at pH 7.5. The salt concentra- 
tions indicated were determined from conductivity measurements on 
individual fractions. 
BHK cells. One form was eluted from heparin-sepha- 
rose in the linear gradient at 1.2 M NaCl and the other 
was eluted in the 3 M NaCl step [l 11. The proportion 
of lower-to-higher affinity forms was about 40%:60%. 
Re-chromatography of a mixture of the two forms gave 
two distinct peaks (Fig. 1). Conductivity meter meas- 
urements howed that the two forms eluted at 1.28 and 
1.91 M NaCl for the lower and higher affinity forms, 
respectively. Because of the high heparin affinity of 
these two forms, dete~ination of the & for heparin- 
antithrombin complexes was made at 10.3 rather than 
physiological ionic strength (I 0.15), to enable a more 
accurate estimate of Kd to be made. The &s of the low 
affinity form for both pentasaccharide and HAH were 
lower than for c1 plasma antithrombin, consistent with 
its elution at a higher salt concentration than the plasma 
species, whereas the high affinity form had an affinity 
similar to that of the /? plasma species (Table I). 
The two N135Q isoforms migrated on SDS-PAGE 
with the same mobility as the j? plasma form of an- 
tithrombin but slightly lower mobility than form III of 
the recombinant wild-type antithrombin (Fig. 2, lanes 
4, 5 and 7). It was known for the jl plasma form, and 
believed to be the case for the recombinant wild-type 
form III, that they carried only three carbohydrate 
chains. These three antithrombins showed higher mo- 
bility than the two forms of recombinant wild-type an- 
tithrombin and the c1 plasma form, which carry four 
carbohydrate chains (Fig. 2, lanes 1, 2 and 6). 
3.2. Carbohydrate composition of HAT isoforms 
We suspected that the reason for the existence of two 
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Fig. 2. SDS-polyacrylamide gel (10%) of different human antithrom- 
bin species, stained with Coomassie brilliant blue. Lanes 1-3, wild- 
type antithrombin fractions I, II and III [l l] respectively; lanes 4 and 
5, recombinant N135Q variant lower and higher affinity forms, respec- 
tively; lanes 6 and 7, a and /3 plasma forms, respectively. 
isoforms of N135Q antithrombin was differences in the 
type of carbohydrate chains present in each form. Spe- 
cific lectin binding was used to characterize the carbo- 
hydrate in each form and confirmed the existence of 
differences between them (Fig. 3). The higher affinity 
form showed the presence of terminal (2 + 3)-linked 
sialic acid, trace amounts of terminal mannose, but no 
terminal galactose. In contrast, the lower affinity form 
showed the presence of high amounts of both terminal 
galactose and terminal (2 + 3)-linked sialic acid, but no 
high mannose chains, consistent with the presence of 
some tri- and tetra-antennary complex carbohydrate 
chains [18]. No O-linked carbohydrate was detectable 
in any of the forms of plasma or recombinant an- 
tithrombin, as shown by failure to stain with Datura 
stramonium agglutinin lectin before or after removal of 
N-linked carbohydrate with N-glycosidase F (data not 
shown). Data on wild-type forms I, II and III, which 
have previously been reported [ 111, are shown for com- 
parison. There is no direct parallel between these three 
forms and the high and low affinity forms of the N135Q 
variant, although form II wild-type, which has higher 
heparin affinity than form I wild-type, has a lower 
amount of highly branched complex carbohydrates 
than form I. This is similar to the relationship between 
high and low affinity N135Q species. The relative 
amounts of high mannose differ, however, between the 
wild-type forms and the N135Q variant forms. 
3.3. Interaction of HAT isoforms with proteinases 
To examine the functional properties of the two 
N135Q isoforms, the ability to form complexes with 
proteinase, and the rates of proteinase inactivation were 
examined. Upon incubation with stoichiometric 
amounts of thrombin or factor X,, both species gave 
high molecular weight complex bands on SDS-poly- 
acrylamide gels (not shown). Rates of inhibition of fac- 
tor X, were obtained for both isoforms that were similar 
to that of o1 plasma antithrombin (Table I). For compar- 
ison, the rate of factor X, inhibition was also deter- 
mined for B plasma antithrombin, since this has not 
been reported previously. It was also similar to that for 
the a plasma species. Enhancements of the rates of pro- 
teinase inhibition by HAH for both N135Q isoforms 
were similar to those of plasma antithrombin species 
(Table I). 
4. DISCUSSION 
We have shown that replacement of Asp-135 by glu- 
tamine, preventing attachment of carbohydrate at the 
fourth glycosylation site of antithrombin, resulted in a 
decrease in the number of isoforms of recombinant an- 
tithrombin from three to two. These two forms were 
able to inhibit factor X, at rates very similar to those of 
both 01 and /? forms of plasma antithrombin. In addi- 
tion, HAH gave similar rate enhancements to those 
found for the plasma antithrombins. The only signifi- 
cant difference in properties was in affinity for heparin. 
Based on previous results for the two carbohydrate 
isoforms, 01 and /?, of plasma antithrombin, in which the 
absence of the fourth carbohydrate chain from position 
135 in the /3 form resulted in a large increase in affinity 
for heparin, we had hoped that the N135Q mutation 
would result in elimination of all of the heparin binding 
heterogeneity present in recombinant BHK-expressed 
antithrombin [l l] and consequently the production of 
only one form of recombinant antithrombin. The failure 
to completely eliminate such heterogeneity upon re- 
moval of the Asp-135 carbohydrate appears to result 
from differences in size of the remaining three carbohy- 
drate chains. The higher affinity form, bearing three 
Table I 
Heparin binding and proteinase inhibitory properties of N135Q antithrombin isofonns compared to those of plasma antithrombin isoforms 
Antithrombin Antithrombin-heparin dissociation constant, K,,, (nM) 
Pentasaccharide HAH 
Rate of factor X, inhibition 
k uncnl bM_’ s-‘) k-J& (uM-’ .s-‘)~ 
a Plasma 500 f 50” 
p Plasma 36+ 3 
N135Q (low affinity) 220 f 20 
N135Q (high affinity) 20f 2 
’ From Fan et al. 1993 [8]. 
b k-,/K,,, values determined in the presence of HAH. 
’ From Olson et al. 1992 [13]. 
93 f 12” 2.3” 1.3” 
7f 2 4.0 1.5 
202 2 2.1 1.4 
9f 2 4.2 1.5 
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Fig. 3. Detection of different types of carbohydrate chain by lectin 
binding. (A) Staining for the presence of a(2 + 3)-linked sialic acid; 
(B) staining for the presence of terminal mannose, indicative of high 
mannose chains; (C) staining for the presence of terminal Gal/I- 
(1 + 4)GlcNAc, indicative of tri- and tetra-antennary complex carbo- 
hydrate chains. 
bi-antennary complex carbohydrate chains, evidenced 
by the presence of sialic acid but no terminal galactose 
[18] and only a trace of high mannose, had properties 
similar to /3 plasma antithrombin, which also bears 
three bi-antennary complex carbohydrate chains. The 
second isoform, although also carrying only three car- 
bohydrate chains, had reduced heparin affinity as a 
result of the increased bulk of the carbohydrate, which 
appeared to include some tri- and tetra-antennary 
chains, evidenced by the presence of significant 
amounts of terminal galactose [18]. This is similar but 
not identical to what we found for recombinant wild- 
type antithrombin expressed in the same BHK cell sys- 
tem [l 11, where two of the three isoforms carried four 
carbohydrate chains, but differed in affinity for heparin 
as a result of the relative amounts of highly branched 
carbohydrate chains in the lowest affinity form I species 
compared to the higher affinity form II species. At the 
time we characterized the three wild-type isoforms it 
was not possible to say whether the effect of the bulk 
of the carbohydrate chains was exerted at only one of 
the four sites of glycosylation (residue 135) or at more 
than one. It now appears that carbohydrate at sites 
other than 135 can influence the affinity of the protein 
for heparin, with the effect being that less carbohydrate 
results in higher affinity. 
In conclusion, we have reduced, but not eliminated, 
the heterogeneity of recombinant antithrombin by elim- 
inating one of the four carbohydrate chains. The failure 
to remove all heterogeneity indicates that carbohydrate 
chain(s) in addition to 135 affect the affinity for heparin 
negatively. The study again highlights the critical im- 
portance of characterizing the number and size of car- 
bohydrate chains in any glycosylated recombinant 
antithrombin before valid comparisons can be made 
between a wild-type and a variant species. 
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